TRANSL CANCER RES 润色咨询

Translational Cancer Research

出版年份:暂无数据 年文章数:336 投稿命中率:60.0%

出版周期:Bimonthly 自引率:9.2% 审稿周期:平均2.46月

前往期刊查询

投稿信息

投稿信息
审稿速度
平均2.46月 (网友贡献,非官方数据)
投稿命中率
60.0% (网友贡献,非官方数据)
审稿费用
暂无数据
版面费用
1390.0元/篇 (网友贡献,非官方数据)
中国人发表比例
2019年中国人文章占该期刊总数量83.63% (2018年为48.70%)
自引率
9.2 %
年文章数
336
期刊官网
点击查看 (点击次数:10410)
点击查看 (点击次数:7423次)
作者需知
暂无数据
期刊简介
稿件收录要求
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; www.thetcr.org) is an Open Access, peer-reviewed journal, published by AME Publishing Company, publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. TCR will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving cancer patients lives. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles. The Official Publication of Society for Translational Cancer Research (STCR),Hong Kong